Clinical Trials Logo

Prostate Cancer clinical trials

View clinical trials related to Prostate Cancer.

Filter by:
  • Recruiting  
  • Page 1 ·  Next »

NCT ID: NCT03254420 Recruiting - Prostate Cancer Clinical Trials

Study Evaluating Late Toxicity Following Intensity-Modulated Radiotherapy and Two Image-Guided Strategies With Corresponding Treatment Margins.

RCMIGI
Start date: August 30, 2016
Phase: Phase 2
Study type: Interventional

The Calypso® System (Varian Medical Systems, Inc., Palo Alto, CA) is a recent technology using electromagnetic transponders implanted within the prostate. It is a real-time target tracking system that takes into account both inter- and intrafractional target motion. So the exact position and movement of the prostate can be determined during radiation therapy treatment. The aim of this study is to assess pelvic late toxicity rate after intensity-modulated radiotherapy (IMRT) when using the Calypso® System with a reduction of treatment margins. In this randomized study, patients will receive IGRT treatment using the Calypso system or a conventional IGRT treatment.

NCT ID: NCT03253978 Recruiting - Prostate Cancer Clinical Trials

SPORT High-Risk Trial Evaluating SABR in Prostate Cancer

SPORT
Start date: January 18, 2016
Phase: N/A
Study type: Interventional

The study will examine stereotactic ablative body radiotherapy (SABR), a new technique to deliver radiotherapy to men with prostate cancer. In addition to this, it will look at the effect of SABR on levels of markers of radiation exposure and bowel damage, along with other potential markers of outcome and side effects. Quality of life and any side effects that develop during and after treatment will also be assessed.

NCT ID: NCT03253458 Recruiting - Prostate Cancer Clinical Trials

Focal Prostate Imaging With CLE and OCT

FPI
Start date: September 1, 2017
Phase: N/A
Study type: Interventional

The current limitations in prostate cancer diagnostics lead to over- and undertreatment for a significant fraction of patients. Confocal Laser Endomicroscopy (CLE) and Optical Coherence Tomography (OCT) are focal imaging modalities with potential for in-vivo prostate imaging. The investigators anticipate that integrating focal imaging with MRI/TRUS fusion will further improve prostate cancer detection and provides a real-time histopathological threedimensional representation of the tumor lesions. This is an investigator-initiated, prospective in-vivo safety and feasibility study with transperineal template mapping biopsies (TTMB) and two focal imaging methods, CLE and OCT, in prostate tissue.

NCT ID: NCT03245736 Recruiting - Prostate Cancer Clinical Trials

Tisotumab Vedotin Continued Treatment in Patients With Solid Tumors.

Start date: August 10, 2017
Phase: Phase 2
Study type: Interventional

The purpose of the trial is to evaluate efficacy and safety of continued treatment with tisotumab vedotin.

NCT ID: NCT03238066 Recruiting - Prostate Cancer Clinical Trials

Salvage Brachytherapy and Interstitial Hyperthermia for Locally Recurrent Prostate Carcinoma Following Radiation Therapy

Prostata-BT-HT
Start date: April 2015
Phase: N/A
Study type: Interventional

Salvage brachytherapy in combination with interstitial hyperthermia for locally recurrent prostate carcinoma following external beam radiation therapy.

NCT ID: NCT03235557 Recruiting - Prostate Cancer Clinical Trials

CyberKnife for Prostate Cancer Patients Aged 70 y or More

ProRobot
Start date: October 2014
Phase: N/A
Study type: Observational [Patient Registry]

Robotic Stereotactic Radiation treatment of prostatic adenocarcinoma of the elderly. Inclusion criteria : T1-T3b, MRI pelvic nodes negative, M0, any Gleason Score, PSA (Prostate Specific Antigen) <30ng/ml. Dose : 36.25 Gy in 5 fractions, in 10 days, considering CAPRA Scores≤5 AND 37.5 Gy in 5 fractions, in 10 days, considering CAPRA Scores>5. Primary objective : acute and late toxicity evaluation at 36 months. Secondary objectives : PSA and MRI response.

NCT ID: NCT03232411 Recruiting - Prostate Cancer Clinical Trials

Biobank for African American Prostate Cancer Research in Florida

Start date: February 6, 2017
Phase: N/A
Study type: Observational

The purposes of this study are: a) to develop a statewide Biobank for prostate cancer among men of African Ancestry in Florida and; b) to examine whether smoking increases the aggressiveness of prostate cancer using several biological approaches. Investigators plan to contact African American prostate cancer patients regarding participation. This project has 3 main components. Eligible patients may choose to participate in any or all parts of the study: Questionnaires; Saliva Samples; Tumor Tissue.

NCT ID: NCT03232164 Recruiting - Prostate Cancer Clinical Trials

PSMA-based 18F-DCFPyL PET/CT and PET/MRI Pilot Studies in Prostate Cancer

Start date: February 2, 2017
Phase: Early Phase 1
Study type: Interventional

The overall goal of this research is to validate and develop a non-invasive imaging biomarker of prostate cancer detection, progression, and recurrence. Development of such a biomarker may be useful to differentiate indolent from aggressive prostate cancer phenotypes allowing for selection of an appropriate risk adaptive therapy.

NCT ID: NCT03232125 Recruiting - Prostate Cancer Clinical Trials

Effect of Ramosetron on Heart Rate-corrected QT Interval During Robot-assisted Laparoscopic Prostatectomy With Steep Trendelenburg Position

Start date: August 1, 2017
Phase: N/A
Study type: Interventional

Intraperitoneal insufflation of carbon dioxide may affect the sympathetic activity that leads to changes in ventricular re-polarization. This in turn can result in changes of heart rate-corrected QT (QTc) interval. Ramosetron is a 5-hydroxytryptamine three receptor antagonist and widely used anti-emetics. However, QTc interval prolongation has been observed in a number of patients after administration of 5-HT3 receptor antagonists. The aim of this study is to evaluate the effects of ramosetron on QTc interval and possible cardiovascular adverse effects during robot-assisted laparoscopic prostatectomy with steep Trendelenburg position.

NCT ID: NCT03228810 Recruiting - Prostate Cancer Clinical Trials

Genetic Biomarker Discovery for Metastatic Prostate Cancer

Start date: May 2, 2017
Phase: N/A
Study type: Observational

Biomarkers from circulating cell-free tumor DNA in peripheral blood will identify patients with metastatic prostate cancer diagnosed with C11 choline PET/CT who will benefit from metastasis-directed radiation, ablative therapies, and/or surgery. Tissue and blood will be collected before treatment. If patients receive androgen deprivation, then blood will be collected after neoadjuvant androgen deprivation but before radiation, ablative therapies, or surgery. Subsequent samples will be obtained at 3 months and 6 months following treatment, after which no further patient contact will occur.